Menu
Fechar
hrs4r
 I want to donate

ROBERT CARRERAS TORRES

Digestive diseases and microbiota
Firma
ROBERT CARRERAS-TORRES
Position
Investigador/a Consolidat - R3
Established Researchers - R3
Projectes
Publicacions

Projectes

Digestive diseases and microbiota

Ayuda de personal Miguel Servet

Codi oficial: CP21/00058 Start date:01/01/2022 Data fi: 31/12/2026 Investigador/a principal: ROBERT CARRERAS TORRES Organisme finançador: INSTITUTO DE SALUD CARLOS III Ajuda: 202,500 €
Digestive diseases and microbiota

Unraveling the influence of gut microbiota and derived metabolites on major depression: A cross-sectional neuroimaging-metabolomics study based on knowledge transfer from irritable bowel syndrome (IBS) and a porcine model: MOODGUT

Codi oficial: 409/C/2022 Start date:13/01/2023 Data fi: 13/01/2028 Investigador/a principal: JESÚS LIBRADO GARCÍA GIL Organisme finançador: FUNDACIO LA MARATO TV3 Ajuda: 0 €

Publicacions

0

Genetic Predictors for Fecal Propionate and Butyrate-Producing Microbiome Pathway are Not Associated with Colorectal Cancer Risk: A Mendelian Randomization Analysis.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2023, 32, 281-286 dx.doi.org/10.1158/1055-9965.EPI-22-0861

Peruchet-Noray L, Dimou N, Sedlmeier AM, Fervers B, Romieu I, Viallon V, Ferrari P, Gunter MJ, Carreras-Torres R, Freisling H

Body Shape Phenotypes and Breast Cancer Risk: A Mendelian Randomization Analysis.

Cancers, 2023, 15 dx.doi.org/10.3390/cancers15041296
0

The relationship between blood pressure and risk of renal cell carcinoma

INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2022, 51, 1317-1327 dx.doi.org/10.1093/ije/dyac042
0

Meta-Analysis and Validation of a Colorectal Cancer Risk Prediction Model Using Deep Sequenced Fecal Metagenomes

Cancers, 2022, 14 dx.doi.org/10.3390/cancers14174214
0

Genome-wide interaction study with smoking for colorectal cancer risk identifies novel genetic loci related to tumor suppression, inflammation and immune response.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2022, 32, 315-328 dx.doi.org/10.1158/1055-9965.EPI-22-0763

Formulari de contacte

About IDIBGI!

 menu